Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

University at Buffalo

- PMLiVE

David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare

Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site

- PMLiVE

Boehringer gains access to Synaffix’s ADC technology through $1.3bn licensing deal

The Lonza company will provide access to its ADC technologies for an undisclosed number of targets

- PMLiVE

GSK gains exclusive option on DualityBio’s preclinical ADC in deal worth over $1bn

The candidate leverages DualityBio's platform against a gastrointestinal cancer target

- PMLiVE

MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease

Approximately one in every 70,000 people are affected by the tumour-causing genetic disease

- PMLiVE

Merck and Daiichi Sankyo to jointly develop T-cell engager in deal worth over $170m

The partners will evaluate MK-6070 as part of a combination treatment for small cell lung cancer

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion

More than 165,000 new cases of bladder cancer are diagnosed in the EU every year

- PMLiVE

Merck’s Keytruda combination recommended by NICE for advanced gastric cancer

More than 6,500 new cases of gastric cancer are diagnosed in the UK every year

- PMLiVE

Merck’s investigational RSV monoclonal antibody clesrovimab shown to protect infants

The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK

- PMLiVE

ICR study reveals Lynparza could treat more advanced prostate cancer patients

Up to 30% of men living with the advanced disease have tumours that contain defects in repairing DNA

- PMLiVE

Merck’s pulmonary arterial hypertension therapy receives CHMP recommendation

Approximately 30,000 people in the EU are currently living with the rare blood disorder

- PMLiVE

Merck’s adult-specific pneumococcal vaccine Capvaxive granted FDA approval

The vaccine is designed to protect against the strains responsible for the majority of adult invasive pneumococcal disease

- PMLiVE

Merck to expand ophthalmology pipeline with acquisition of EyeBio in deal worth up to $3bn

Merck will gain access to EyeBio’s Restoret to prevent and treat retinal vascular leakage-associated vision loss

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links